Anzeige
❌
Mehr »
Donnerstag, 22.10.2026 - Börsentäglich über 12.000 News
URAN: JETZT WIRD ES SPANNEND
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
VT

WKN: A3CPQG | ISIN: US92337R1014 | Ticker-Symbol:
NASDAQ
22.10.26 | 18:01
30,565 US-Dollar
-2,04 % -0,635
1-Jahres-Chart
VERA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
VERA THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur VERA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
16:18Vera Therapeutics plans FDA filing for IgAN drug in Q4 20262
16:06Vera Therapeutics Announces Positive ORIGIN 3 Final Efficacy Analysis of TRUTAKNA' (atacicept-vymj) in IgA Nephropathy Presented at ASN Kidney Week 2026 and Published in the New England Journal of Medicine2
02.10.Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)1
02.10.Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026668BRISBANE, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that there will be multiple presentations at the...
► Artikel lesen
16.09.Vera Therapeutics Reports Positive Two-Year Phase 3 Trutakna Results9
15.09.Why is Vera Therapeutics stock reversing its premarket gains?6
15.09.TD Cowen reiterates Buy on Vera Therapeutics stock on kidney data6
VERA THERAPEUTICS Aktie jetzt für 0€ handeln
15.09.Vera Therapeutics stock maintained at Strong Buy by Raymond James3
15.09.Vera Therapeutics, Inc. - 8-K, Current Report2
15.09.Vera Therapeutics Announces TRUTAKNA (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy582TRUTAKNA, the first and only FDA-approved BAFF and APRIL inhibitor, met all prespecified endpoints, including unprecedented placebo-adjusted estimated glomerular filtration rate (eGFR) and composite...
► Artikel lesen
10.09.Vera Therapeutics: Erfolgreicher Start für Nierenmedikament TRUTAKNA5
04.09.Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)1
12.08.Goldman Sachs lowers Vera Therapeutics stock price target to $804
10.08.Vera Therapeutics GAAP EPS of -$1.52 beats by $0.047
10.08.Vera Therapeutics, Inc. - 10-Q, Quarterly Report3
07.08.Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)3
10.07.Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)4
10.07.Weekly Buzz: Johnson & Johnson, Vera Therapeutics Get FDA Nod; Vertex Pharmaceuticals Snaps Up Crinetics Pharmaceuticals; Satellos Bioscience Aces DMD Trial; Ionis Pharmaceuticals Misses Key Goal1.922NEW BRUNSWICK (dpa-AFX) - This week featured a steady stream of regulatory milestones, strategic dealmaking, and pivotal clinical trial updates, alongside missed trial goals across the biotech...
► Artikel lesen
09.07.Führungswechsel bei Vera Therapeutics: Nancy Boman wird neue Chief Regulatory Officer4
09.07.Vera Therapeutics names Nancy Boman as chief regulatory officer4
1 2 3 Weiter >>
53 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1